Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
A team of researchers at UHN has developed a novel research tool that could help to advance new treatments to reverse vision loss caused by age-related macular degeneration (AMD).
AMD is a leading cause of vision loss in older adults. It's characterized by the loss and/or dysfunction of the cells that initiate vision. These cells – known as photoreceptors – detect light, transform it into electrical signals that are then relayed through nerve cells to the brain, where the signals are translated into images.
Researchers are currently exploring cell replacement therapy as a potential treatment for AMD. Cell replacement therapy involves the surgical transplantation of healthy photoreceptors from a donor into a host, replacing the lost or dysfunctional photoreceptors.
"Once transplanted, donor photoreceptors need to mature and establish functional connections to the host cells to be able to dispatch electrical signals to the brain," says Dr. Valerie Wallace, a Senior Scientist at the Krembil Research Institute. "Presently, it appears that transplanted cells are not making these important connections, and we don't know why."
To address this, Dr. Wallace and her research team developed an efficient and inexpensive assay – investigative procedure – to identify and study the mechanisms that control the maturation of donor photoreceptors.
Using this assay, the researchers showed that the following three factors influence the initial stages of connectivity: the ROCK protein, which controls the growth of eye cells; Müller glia, which are cells that provide structural and functional support to nerve cells; and the CRX gene, which is important for the development of photoreceptors.
"We have established a novel assay to help us understand the mechanisms that regulate connections between donor and host cells," concludes Dr. Wallace. "Our assay could reveal factors to promote these connections, which are crucial for cell replacement therapy to successfully restore vision in patients with AMD and other diseases that cause photoreceptor degeneration."
This work was supported by Brain Canada, the Foundation Fighting Blindness, the Ontario Institute for Regenerative Medicine, the Krembil Foundation, the Canada First Research Excellence Fund and the Toronto General & Western Hospital Foundation. MS Shoichet is a Tier I Canada Research Chair in Tissue Engineering.